CAPR Stock Jumps As Lancet Data And Upgrade Shift Odds

Capricor Therapeutics Inc. stocks have been trading up by 97.39 percent amid strong optimism over its cardiology pipeline developments.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CAPR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Peer‑reviewed HOPE‑3 data show deramiocel slowed upper‑limb decline by 54% versus placebo in Duchenne muscular dystrophy, with added cardiac benefits in largely non‑ambulatory patients.
Capricor’s deramiocel BLA is under active FDA review with a PDUFA decision due on 2026/08/22, putting CAPR on a clear binary event path.
The company is challenging FDA briefing analyses that relied on an older statistical plan, while emphasizing HOPE‑3 met its pre‑specified primary endpoint under SAP v3.0.
Cantor Fitzgerald upgraded CAPR to Overweight and hiked its target to $28, as Oppenheimer reiterated Outperform and called the roughly 70% pre‑AdCom slide a favorable risk‑reward setup.
Capricor ended Q2 2026 with about $238M in cash and says it can fund at least 12 months of operations while moderating commercial spend and awaiting deramiocel decisions.

Live Update At 07:47:32 EDT: On Friday, August 14, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 97.39%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CAPR trades like a classic biotech catalyst name, and the chart proves it. In late July, shares collapsed from around $19.70 on 2026/07/24 to $6.57 by 2026/07/29 after regulatory headlines and advisory committee pressure. Since then, CAPR has been grinding in the low‑single digits, with recent closes stuck near $4.00–$4.20, showing that traders are still hesitant but willing to probe the long side on news pops.

Intraday action tells the real story. In the 5‑minute tape, CAPR recently ripped from the low‑$7s to the high‑$8s and low‑$9s, with multiple pushes toward $9.35 before dipping back into the $8s. That kind of fast spike‑and‑fade behavior is textbook for a crowded biotech trade heading into a binary FDA decision.

More Breaking News

Fundamentally, Capricor remains pre‑revenue. Recent reports show negative earnings, heavy R&D around deramiocel, and a cash burn that produced about -$34M in free cash flow last quarter. But the balance sheet carries roughly $278.6M in cash and short‑term investments against minimal debt, plus a current ratio above 8. CAPR is essentially a one‑main‑asset, well‑funded, high‑volatility vehicle tied to what the FDA decides next.

Why Traders Are Watching CAPR Into The FDA Decision

CAPR is front and center on many biotech watchlists because the science just took a big step up in credibility. The Lancet publication of the Phase 3 HOPE‑3 trial gives deramiocel something every small‑cap biotech wants: independent, high‑profile validation. The trial showed a 54% slowing of upper‑limb function decline versus placebo in Duchenne muscular dystrophy, plus meaningful cardiac benefits, in a tough, largely non‑ambulatory population. For traders, that reduces the “is the drug real?” question.

At the same time, CAPR is locked in a tense back‑and‑forth with the FDA. Capricor says agency staff leaned on an outdated statistical analysis plan (SAP v1.1) for post‑hoc work, while the pivotal HOPE‑3 trial met its primary endpoint using the finalized SAP v3.0. The company even released its own slide deck to shape the narrative. That kind of public pushback tells traders two things: management is confident in the data, and the review process is politically charged.

Despite a negative advisory committee vote on the cardiomyopathy indication, the FDA has kept the deramiocel BLA under active review. The key PDUFA date, 2026/08/22, now acts like a magnet for CAPR price action. Every headline, every analyst note, gets filtered through that date.

Wall Street is split, which is exactly what active traders want. Oppenheimer reiterated an Outperform rating, pointing out that the single AdCom question’s wording looks favorable and that a roughly 70% share price dive into the meeting created what they see as attractive risk‑reward. Cantor Fitzgerald went further, upgrading CAPR to Overweight and blasting its target from $3.50 to $28. On the other side, B. Riley has stepped back twice, slashing its target to $5 while holding a Neutral stance. That disagreement builds the tension that fuels big squeezes and brutal flushes around each news drop.

Conclusion

Capricor’s recent Q2 update reminds traders what this story really is: a pre‑revenue biotech burning cash to chase one major shot on goal. The company reported no product revenue and a widening loss as it gears up for potential commercialization of deramiocel. Operating cash flow sat around -$29.3M for the latest quarter, and free cash flow about -$34M. Those are big red numbers, but CAPR also reported roughly $238M in cash, cash equivalents, and marketable securities and says that runway should cover at least the next 12 months.

That cash plus a very low debt load gives Capricor time to see the FDA process through. Management is already moderating commercial spend until there is more clarity, pausing most non‑deramiocel programs and even pushing a distribution dispute with NS Pharma into arbitration. Everything now leans on deramiocel and that 2026/08/22 PDUFA date.

For traders, CAPR is a classic binary biotech setup: strong Phase 3 data now blessed by The Lancet, vocal pushback against FDA skeptics, and a Street split between aggressive bulls and cautious skeptics. The intraday tape shows plenty of liquidity and volatility for disciplined day and swing trading, but the risk is real and concentrated in a single regulatory call.

This is exactly the kind of name Tim Sykes and Tim Bohen talk about when they say, “Trade the catalyst, not the story.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” CAPR gives you a defined catalyst, a clear timeline, and wild swings on every headline—perfect for prepared traders who cut losses fast and never confuse a research idea with personal advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!